Alright, I've watched this go on for too long.
Incyte is a very wonderful company and not many people
seem to see this. True, I may work for them but I'm
not trying to "sell" any hype. Incyte keeps coming
out with good news tidbits and nothing is done...
Where are the buyers?? We change names to show that
Genome Systems' (which was very profitable here in St.
Louis) ideals have been incorporated and there's no
relief in the stock drop. For those of you who haven't
been following, Incyte has changed to allow small
biotechs and academia (which Genome Systems had been
catering to for nearly a decade) access to it's database
via the internet. Now you can't tell me that the
internet/biotech combination isn't a winner?? Oh, and as for those
people coming on our board who own other stock...
They're scared of this dip too but they choose to use
propaganda to scare us worse. Case in point:
So what should be your reaction? I say stick with
INCY and leave those other guys to play their games.
We will be on top when the smoke clears. If I didn't
believe in them this strongly then I sure as hell
wouldn't be working for them. -My 2 Cents-
just learning myself
but as i understand it... the stock jumped say $10 in
value the other day without a trade i.e. overnight. the
market abhors a vaccuum ... therfore the stock traded
down to fill the gap befor continuing uptrend.
Good post. Ventner is a great salesman. But I can
say this with a good degree of accuracy. The
management of Incyte has the attention and
the genome and pharmaceutical
community. INCY may
not have the scientists
that the Cambridge crowd
has, but it does have
the computers, the contracts,
and the patents.
I covet this stock, MLNM, AMGN,
and now CBMI,
soon to be CURIS. It takes balls to
and hold them. How many people bailed on
this week at 60 or MLNM at 105 and feel like
I hope that was supposed to be a compliment and
not a reflection of Microsoft's recent problems with
the Justice Department..seriously incyte should be
valued much higher than it currently is.
way..pardon my ignorance.. but what did you mean by " filling
the gap between 100 -110"?
Anyway I'm long the
stock... wish everyone the best.
any kick-ass scientists that can make bold
declarations and keep the press hypnotized and off-track.
Really, Incyte should invest in a Venter or Hasseltine.
Have you guys read the Genome Newsweek issue and the
Drosophila Science issue? Man... what huge egos. But they
get a lot of good press -- even when they don't
But, honestly I don't see the
Stock goes up and down, profit taking
Investors all have different situations,
but what a
buying opportunity here,
on the UP leg after the
bungee dive last week.
You won't see price this
low again for the
rest of the year.
can bet on it.
Incy is just filling the gap between 100 and 110. was up late last night and read somewhere (CBSmw???) that an analyst called incy the msft of gene stocks. incy will be a fabulous long long hold.
This co. has something on the order of 160
patents on genes and it freely licences the information
to any drug co. Therefore if any or all come up with
marketable drugs..these guys gets royalties..now getting
drugs approved takes years but check back in the wall
street journal of a few months ago.. these guys are
good!! So why pray tell is the stock down?
...IMHO, of course.
I am quite convinced
that INCY will make a great deal of money and I have
spent some time trying to devise a plausible analogy.
Any help in devising such an analogy is welcome. The
one presented below is not perfect. Also, let me
state that I am NOT a patent
Drugs/compounds (products) created from the sequences are indeed
patentable. Precedent for this is the fact that products from
other compounds/chemicals/whatever are patentable. One
example is aspartame, the sweetener, which had a patent
that includes taste. So definite precedent exists.
(There are many other examples, if anyone can clarify or
enlighten please do so.) But the _products_ are not being
given away for free (unless I grossly misunderstand the
Which leads to the genetic
information itself. Here is the flawed analogy I conjured:
let's say you wrote a book and published it. You get a
royalty everytime someone buys it and your permission
must be given before someone reprints any part of it,
but it also is available free to the public via
public libraries. You still will make money and some
people read your work for free. Now let me tell you a
few problems with my analogy...first, books have a
copyright, not a patent. Second, won't everyone just use the
library? Perhaps, but some aspects, including SNPs, aren't
so easy to deal with. Third, in 20 years, I envision
using my handy table top sequencer to get the dirt on
my kid's sweeties, (it's an exaggeration--don't get
excited) so everyone will be able to get the information
quickly and easily, so it doesn't matter if it's publicly
available. (There are more flaws and I'm sure I'll see them
Even if everyone uses the public library for gene
data, that still should not effect in any way the
products created from the DNA sequences already patented
by INCY. So INCY's patent and royalty position is
very strong. INCY has been patenting for years and
will continue to receive patents for years to come.
Finally, INCY will receive royalties from current and past
database users from drugs created from use of INCY's
Itvestor, I hope that helps. My apologies for the flawed
analogies, but I hope they work for you. Perhaps a
knowledgable patent attorney or chemist can help. Also, thank
you for your kind comment.
Good Luck in your